4D Molecular Therapeutics Holds Annual Stockholder Meeting
Ticker: FDMT · Form: 8-K · Filed: May 24, 2024 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
4D Molecular Therapeutics held its annual shareholder meeting on May 21st, time for votes.
AI Summary
On May 21, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report indicating that it held its Annual Meeting of Stockholders. The primary purpose of the meeting was for security holders to vote on various matters presented by the company. The filing does not detail the specific proposals or the outcomes of the votes.
Why It Matters
This filing confirms that 4D Molecular Therapeutics held its annual shareholder meeting, a routine corporate governance event where key decisions are made and voted upon by investors.
Risk Assessment
Risk Level: low — This is a routine corporate governance filing about a shareholder meeting, not indicating any new financial or operational risks.
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- May 21, 2024 (date) — Date of earliest event reported
FAQ
What was the date of 4D Molecular Therapeutics' Annual Meeting of Stockholders?
The earliest event reported in the 8-K filing was on May 21, 2024, which was the date of the Annual Meeting of Stockholders.
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Submission of Matters to a Vote of Security Holders, specifically related to the Annual Meeting of Stockholders.
Where is 4D Molecular Therapeutics, Inc. incorporated?
4D Molecular Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for 4D Molecular Therapeutics, Inc.?
The address of the Principal Executive Offices is 5858 HORTON STREET #455, EMERYVILLE, California, 94608.
Does this filing specify the proposals voted on at the Annual Meeting?
No, this filing indicates that matters were submitted to a vote of security holders but does not specify the details of the proposals or the voting outcomes.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-05-24 16:28:05
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share FDMT Nasdaq Glo
Filing Documents
- d649174d8k.htm (8-K) — 27KB
- 0001193125-24-147093.txt ( ) — 150KB
- fdmt-20240521.xsd (EX-101.SCH) — 3KB
- fdmt-20240521_lab.xml (EX-101.LAB) — 18KB
- fdmt-20240521_pre.xml (EX-101.PRE) — 11KB
- d649174d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 4D MOLECULAR THERAPEUTICS, INC. Date: May 24, 2024 By: /s/ Uneek Mehra Uneek Mehra Chief Financial and Business Officer